The country’s daily requirement is over 10 million doses against the production of 2.9 million. The Sputnik V vaccine, which got the nod on Monday, will help bridge the gap, albeit marginally.
The recent surge in Covid-19 infections, the central bank says, adds uncertainty to the outlook on domestic growth as restrictions could dampen demand improvement and delay the return of normalcy.
India’s pharma industry is reimagining itself. This is not just borne out of the necessities brought forth by the pandemic, but is a blueprint to thrive and to succeed in this new world.
Aided by strong demand recovery, credit ratio rebounds to 1.33 in H2FY21, from 0.54 in H1FY21. GDP could grow at 11% in FY22, but the resurgence in Covid-19 cases is a key downside risk, says CRISIL.
RDIF has tied up with nearly a dozen contract manufacturers with idle capacity to produce some 1.5 billion doses of Sputnik V annually, more than what Serum and Bharat Biotech will jointly produce.
The Covid-19 pandemic failed to affect the bulls’ spirits, as benchmark indices saw absolute annual gains between 75.2% and 117.2% while FPIs pumped in a record ₹2.74 lakh crore into equities.
In the context of vaccination, effective communication should deliver clarity around who, when, where, and how much the vaccine will cost. And India's vaccine deployment can be a great case study.
The second phase of the Covid-19 vaccine, which is currently underway, requires the private sector's involvement more than ever before. And the sector is rising up to the challenge.
According to a Capgemini Research Institute survey, while the pandemic propelled digital adoption, physical channels continue to remain significant for financial services consumers.
